Clinical Advisory Board

ROBERT HOLLOWAY, M.D. – CHAIRMAN

 

Medical Director, Gynecologic Oncology, AdventHealth Cancer Institute

 

Dr. Holloway is the principal investigator for VIRO-15 and has served on several committees of the Society of Gynecologic Oncology (SGO), including its Board of Directors. He is a Fellow of the American College of Surgeons and founding member of the Global Robotics Institute at AdventHealth, Orlando. Dr. Holloway has authored or coauthored more than 100 peer-reviewed articles. Dr. Holloway completed medical school at Vanderbilt University Medical Center, residency at University of Alabama, Birmingham, and fellowship at Georgetown University Hospital.

ROBERT COLEMAN, M.D.

 

Gynecologic Oncology, Chief Scientific Officer, US Oncology Research

 

Dr. Coleman currently serves on the Board of Directors of Gynecologic Oncology Group and is a Director of GOG-Partners. In addition, he has served as President of SGO and as a Council member and Secretary Treasurer for the International Gynecologic Cancer Society, for which he is President-Elect (2020-2022). Dr. Coleman has authored or coauthored more than 300 peer-reviewed articles. Dr. Coleman completed medical school at Creighton University School of Medicine, residency at Northwestern University Medical Center, and gynecologic oncology fellowship at the University of Texas MD Anderson Cancer Center. He served as Professor and Ann Rife Chair in Gynecology at University of Texas, M.D. Anderson Cancer Center and Executive Director, M.D. Anderson Cancer Network Research until April 2020.

ALBERT A. MENDIVIL, M.D.

 

Co-Director, Gynecologic Oncology, Hoag Memorial Hospital Presbyterian

 

Dr. Mendivil, site principal investigator for VIRO-15, serves as Co-Director, Gynecologic Oncology and Complex Pelvic Surgery, Hoag Hospital. He has authored or coauthored more than 40 peer-reviewed publications and has been the principal investigator or site sub-investigator on 20+ clinical trials. Dr. Mendivil received his medical degree from the University of Utah School of Medicine and completed internship and residency training in Obstetrics and Gynecology at the University of California, Irvine, and fellowship training in gynecologic oncology at the University of North Carolina, Chapel Hill.

THOMAS J. HERZOG, M.D.

 

Deputy Director of the University of Cincinnati Cancer Institute and Vice-Chair of Quality and Safety for Obstetrics and Gynecology, University of Cincinnati College of Medicine

 

Dr. Herzog is Secretary Treasurer and Associate Director of the GOG Foundation. In addition, he has served on the leadership board or council of SGO, the Foundation for Women’s Cancer, Board of Governors for the American College of Surgeons, American Board of Obstetrics and Gynecology, and International Gynecologic Cancer Society. Dr. Herzog has authored/co-authored 290+ peer-reviewed articles. Dr. Herzog graduated from the University of Cincinnati College of Medicine and completed his residency at Good Samaritan Hospital in Cincinnati and a fellowship in gynecologic oncology at the Washington University School of Medicine, St. Louis, MO.

DAVID M. O’MALLEY, M.D.

 

Professor and Division Director, Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute

 

Dr. O’Malley is the clinical trial advisor/lead for ovarian cancer within GOG Partners, a committee member for the NCI Gynecologic Cancer Steering Committee’s Ovarian Task Force and the NRG Oncology (Ovarian Cancer and Developmental Therapeutics Groups), and a panel member of the national Comprehensive Cancer Network Guidelines for Ovarian Cancer. He has authored 130+ peer-reviewed publications. Dr. O’Malley received his medical degree from the Wayne State University School of Medicine, and completed his residency at Case Western Reserve University (MetroHealth) and the Cleveland Clinic Foundation, and gynecologic oncology fellowship at Yale University.

ALAN FORSYTHE

 

Forsythe & Bear, LLC

 

Dr. Forsythe has had a distinguished career in pharmaceutical drug development. As Vice President of Corporate Biomedical Information at Amgen, Alan led the Biostatistics, Epidemiology and Health Economics departments. In his role, Dr. Forsythe reviewed and approved all Amgen clinical studies, clinical publications and presentations and was responsible for ensuring appropriate reimbursement for Amgen products from government agencies and private insurance carriers.

 

Alan is an Elected Fellow and past officer of the American Statistical Association and is the author of over 100 papers on statistical methods, epidemiology and clinical trial design. Dr. Forsythe received his B.S in Mathematics from City University of New York, his M.S. in Biostatistics from Columbia University, and his Ph.D. in Biometry from Yale University.

Expanded Access Policy

Genelux Corporation is committed to developing safe and effective next-generation immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our goal is to ensure access to our investigational therapies at the appropriate time and in a clinically appropriate manner for patients.

Outside of our clinical trials, we may provide physician-requested expanded access to its investigational products under limited situations. This is initiated when the primary purpose is to diagnose, prevent, or treat a serious condition in a patient, which is different from a clinical trial where more comprehensive safety and efficacy data are collected. At Genelux, we recognize and understand the need for an early/expanded access policy for patients who have serious or immediately life-threatening disease and have limited available treatment options.

The request for access to a Genelux investigational drug will be considered only if the patient is an eligible patient, meaning:

  • The patient has a serious or life-threatening disease or condition with no comparable or satisfactory alternative therapies; and
  • The patient is not eligible for or unable to participate in a clinical trial

In addition, prior to setting up an expanded access program or granting a request from an eligible patient’s physician, Genelux will consider whether:

  • The investigational drug is currently in clinical development with sufficient evidence of safety and effectiveness for patient’s specific condition;
  • Providing the investigational therapy as part of an expanded access program will interfere with clinical trials that could support the investigational therapy’s development or marketing approval for the treatment indication; and
  • We have adequate supply of investigational drug.

At this time, based on these factors, Genelux believes that participation in one of our clinical trials is the only appropriate way to access our investigational therapies.

If the investigational drug is approved by a regulatory agency for commercial use, including provisional approval, existing expanded access programs will be phased out or modified accordingly.

Patients interested in seeking an expanded access to a Genelux investigative drug should talk to their physician. All requests must be made by the patient’s treating physician by email at EAP@genelux.com. We will, in general, acknowledge receipt of a request for expanded access within five business days. We may ask for more detailed information to fully evaluate a request.

The request for access to an investigative drug can only be considered if the requesting physician agrees to obtain applicable regulatory and ethics committee approvals. We may deny access if the treating physician cannot guarantee an appropriate storage and handling of the investigative drug, which typically requires a temperature controlled deep freezer and follows Biosafety Level 2 safety procedures and precautions. The treating physician must agree to comply with regulatory obligations, including safety monitoring and reporting.

For more information on expanded access from the FDA, click here.